Total trials
287
Active
34
Phase 3
78
Total enrollment
64,900
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| IPN10200 | — | — | — | — | 6 | ||
| Elafibranor | — | — | — | — | 6 | ||
| Botulinum toxin type A | — | 46 | |||||
| IPN60340 + azacitidine + venetoclax | — | — | — | — | — | 1 | |
| Elafibranor 80mg | — | — | — | — | — | 1 | |
| Dysport | — | — | — | — | — | 2 | |
| IPN10200 dose A | — | — | — | — | — | 1 | |
| IPN10200 dose B | — | — | — | — | — | 1 | |
| Elafibranor 80 mg | — | — | — | — | — | 1 | |
| Elafibranor 120 mg | — | — | — | — | — | 1 | |
| IPN60300 | — | — | — | — | — | 1 | |
| IPN10200 Placebo | — | — | — | — | — | 1 | |
| IPN01195 | — | — | — | — | — | 1 | |
| IPN01194 | — | — | — | — | — | 1 | |
| IPN01203 | — | — | — | — | — | 1 | |
| Tovorafenib | — | — | — | — | — | 1 |
Next readouts
- 2023-06-01
- 2026-05-28
- 2026-06-01
- 2026-08-31
- 2026-12-15
- 2026-12-15
- 2026-12-17
- 2027-03-26
- 2027-10-31
- 2028-03-20
Top conditions
- Acromegaly34
- Prostate Cancer21
- Cervical Dystonia11
- Neuroendocrine Tumors9
- Muscle Spasticity7
- Spasticity6
- Renal Cell Carcinoma6
- Cerebral Palsy4
Frequently asked questions about Ipsen
- How many clinical trials does Ipsen have on ClinicalTrials.gov?
- Ipsen is listed as the lead sponsor on 287 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ipsen's trials are in Phase 3?
- 78 of Ipsen's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does Ipsen focus on?
- Ipsen's most-studied conditions on ClinicalTrials.gov are Acromegaly, Prostate Cancer, Cervical Dystonia, Neuroendocrine Tumors, Muscle Spasticity.
- When are Ipsen's next clinical trial readouts?
- Ipsen has 10 upcoming primary-completion readouts tracked here; the soonest is “Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)”, expected around 2023-06-01.